Galectin Therapeutics (GALT) has a clinical trial milestone to watch for this month, which is related to its lead drug candidate, Belapectin, in metabolic dysfunction-associated steatohepatitis, or MASH, with cirrhosis. Belapectin is a carbohydrate-based drug that inhibits galectin-3, a protein involved in fibrosis and inflammation in chronic liver diseases. A phase III trial, evaluating the pote...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.